Anavex Life Sciences Terminates Material Agreement
Ticker: AVXL · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1314052
| Field | Detail |
|---|---|
| Company | Anavex Life Sciences Corp. (AVXL) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: termination, agreement
TL;DR
Anavex just terminated a big deal, details TBD.
AI Summary
Anavex Life Sciences Corp. announced on July 24, 2024, the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it indicates a significant change in contractual relationships for the company.
Why It Matters
The termination of a material definitive agreement can impact future operations, partnerships, or financial obligations of Anavex Life Sciences Corp.
Risk Assessment
Risk Level: medium — The termination of a material definitive agreement introduces uncertainty regarding the company's strategic direction and financial stability.
Key Players & Entities
- ANAVEX LIFE SCIENCES CORP. (company) — Registrant
- July 24, 2024 (date) — Date of earliest event reported
- 630 5th Avenue (location) — Principal executive offices address
FAQ
What specific material definitive agreement was terminated by Anavex Life Sciences Corp.?
The filing does not specify the name or details of the terminated material definitive agreement.
Who was the counterparty to the terminated material definitive agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination of the material definitive agreement?
The earliest event reported is July 24, 2024, which is the date of the report and likely the effective date or announcement date of the termination.
Does the termination of this agreement have any immediate financial implications for Anavex Life Sciences Corp.?
The filing does not provide specific details on the immediate financial implications of the agreement's termination.
Are there any other material definitive agreements that Anavex Life Sciences Corp. is currently party to that are at risk of termination?
This filing only addresses the termination of one specific material definitive agreement and does not provide information on other agreements.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-30 17:20:53
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share AVXL The Nasdaq Stock Mar
Filing Documents
- e5843_8k.htm (8-K) — 23KB
- 0001731122-24-001160.txt ( ) — 192KB
- avxl-20240724.xsd (EX-101.SCH) — 3KB
- avxl-20240724_lab.xml (EX-101.LAB) — 33KB
- avxl-20240724_pre.xml (EX-101.PRE) — 22KB
- e5843_8k_htm.xml (XML) — 4KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. Anavex Life Sciences Corp. (the " Company ") was party to a Controlled Equity Offering SM Sales Agreement, as amended and restated by the Amended and Restated Sales Agreement dated May 1, 2020 (the " A&R Sales Agreement ") with Cantor Fitzgerald & Co. and SVB Securities LLC (the " Sales Agents "), with respect to an "at-the-market" offering program under which the Company could offer and sell, from time to time at the Company's sole discretion, shares of its common stock, par value $0.001 per share, through the Sales Agents. On July 24, 2024, the Company terminated the A&R Sales Agreement. There are no penalties associated with the termination of the A&R Sales Agreement. A copy of the A&R Sales Agreement was filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the SEC on May 1, 2020 (the " 2020 Form 8-K ").
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANAVEX LIFE SCIENCES CORP. /s/ Christopher Missling Name: Christopher Missling, PhD Title: Chief Executive Officer Date: July 30, 2024